c-MET (蛋白 | 抗体 | cDNA 克隆 | ELISA 试剂盒)

All c-MET reagents are produced in house and quality controlled, including 24 c-MET Antibody, 2 c-MET ELISA, 52 c-MET Gene, 12 c-MET Lysate, 12 c-MET Protein, 3 c-MET qPCR. All c-MET reagents are ready to use.

c-MET Protein (12)

c-MET Antibody (24)

c-MET ELISA 试剂盒(即用型)& ELISA 抗体对套装(非即用型)(2)

c-MET cDNA Clone (52)

NM_000245.2

克隆载体 cDNA 产品

In lentiviral vector

NM_008591.2

克隆载体 cDNA 产品

In lentiviral vector

XM_006236129.2

克隆载体 cDNA 产品

In lentiviral vector

NM_001168629.1

克隆载体 cDNA 产品

In lentiviral vector

c-MET Lysate (12)

c-MET 分子背景

Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that has been shown to be overexpressed and/or mutated in a variety of malignancies. HGFR protein is produced as a single-chain precursor, and HGF is the only known ligand. Normal HGF/HGFR signaling is essential for embryonic development, tissue repair or wound healing, whereas aberrantly active HGFR has been strongly implicated in tumorigenesis, particularly in the development of invasive and metastatic phenotypes. HGFR protein is a multifaceted regulator of growth, motility, and invasion, and is normally expressed by cells of epithelial origin. Preclinical studies suggest that targeting aberrant HGFR signaling could be an attractive therapy in cancer.

c-MET 参考文献

  • McGill GG, et al. (2006) c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem. 281(15): 10365-73.
  • Garcia S, et al. (2007) c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. British journal of cancer. 96(2): 329-35.
  • Socoteanu MP, et al. (2008) c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 14(19): 2990-4.
  • Kong DS, et al. (2009) Prognostic significance of c-Met expression in glioblastomas. Cancer. 115(1): 140-8.